BioCryst Pharmaceuticals, Inc.
BCRX
$10.34
$0.505.08%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 1,441.69% | -2,255,762.50% | 1,017.50% | 191.92% | 140.12% |
| Total Depreciation and Amortization | 55.93% | 220.54% | 7.15% | 24.23% | 2.81% |
| Total Amortization of Deferred Charges | -55.77% | -72.61% | -- | -- | -- |
| Total Other Non-Cash Items | -14.24% | 2,066.29% | 27.77% | -5.70% | 12.87% |
| Change in Net Operating Assets | -230.96% | -14.92% | 137.30% | 85.00% | 112.99% |
| Cash from Operations | 152.63% | -124.56% | 5,700.61% | 404.84% | 3,119.15% |
| Capital Expenditure | -16.76% | -181.82% | -18.81% | -2,177.97% | -15.48% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -475.14% | 712.23% | -514.16% | 68.06% | 1,377.51% |
| Cash from Investing | -478.16% | -1,091.50% | -569.11% | 59.88% | 1,289.34% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 82.02% | -59.11% | -55,275.84% | -10,844.96% | -18,867.66% |
| Issuance of Common Stock | 82.13% | 714.36% | -- | 27.59% | 1,142.75% |
| Repurchase of Common Stock | -326.33% | 12.14% | -63.77% | -140.61% | 52.93% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 84.86% | 77,887.15% | -5,320.54% | -4,716.48% | -3,648.02% |
| Foreign Exchange rate Adjustments | -102.58% | -115.96% | 94.48% | -154.99% | 1,050.35% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -0.22% | 14,602.69% | -27.26% | -120.51% | -186.13% |